In three prevalent resistance settings – ESR1 mutation, NF1 loss and FOXA1 mutation – this combination resensitised resistant cells to oestrogen deprivation and restored sensitivity to selective oestrogen receptor degraders (SERDs), providing a promising option for patients with advanced ER+ breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.